The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on ≥ 7 years of follow-up from CheckMate 025 trial.
 
Saby George
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Merck; Pfizer; QED Therapeutics; Sanofi; Seattle Genetics/Astellas
Research Funding - Agensys (Inst); Aravive (Inst); Aveo (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Surface Oncology (Inst)
 
James Larkin
Honoraria - Agence Unik; Bristol-Myers Squibb; Cambridge Healthcare research; Eisai; Incyte; Merck Serono; Novartis; Pfizer; RCGP; Royal College of Physicians; touchEXPERTS; touchIME; VJOncology
Consulting or Advisory Role - Agence Unik; Apple Tree Partners; Aptitude Health; AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences; Debiopharm Group; eCancer; Eisai; EUSA Pharma; GlaxoSmithKline; Goldman Sachs; Incyte; Insel Gruppe; iOnctura; Ipsen; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Ultimovacs
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Pierre Fabre; Roche/Genentech
 
Kateryna Chepynoga
No Relationships to Disclose
 
Daniel Sharpe
Employment - Parexel
 
Tuli De
Employment - Parexel/CALYX
 
Matthew Dyer
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Flavia Ejzykowicz
Employment - Bristol-Myers Squibb; Bristol-Myers Squibb; Merck
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Jessica May
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Murat Kurt
Employment - Bristol Myers Squibb Foundation
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation
Travel, Accommodations, Expenses - Bristol Myers Squibb Foundation